


## Ocifisertib

<b>Cat. No.:</b>	HY-12300		
<b>CAS No.:</b>	1338806-73-7		
<b>Molecular Formula:</b>	C <sub>33</sub> H <sub>34</sub> N <sub>4</sub> O <sub>3</sub>		
<b>Molecular Weight:</b>	534.65		
<b>Target:</b>	Polo-like Kinase (PLK)		
<b>Pathway:</b>	Cell Cycle/DNA Damage		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (187.04 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM		1.8704 mL	9.3519 mL	18.7038 mL
		5 mM		0.3741 mL	1.8704 mL	3.7408 mL
10 mM			0.1870 mL	0.9352 mL	1.8704 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.5 mg/mL (4.68 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (4.68 mM); Suspended solution; Need ultrasonic</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.5 mg/mL (4.68 mM); Clear solution</li> </ol>					

### BIOLOGICAL ACTIVITY

<b>Description</b>	CFI-400945 free base is a potent, selective and orally bioavailable PLK4 inhibitor with a K <sub>i</sub> and an IC <sub>50</sub> of 0.26 nM and 2.8 nM, respectively.			
<b>IC<sub>50</sub> &amp; Target</b>	PLK4 2.8 nM (IC <sub>50</sub> )	AURKA 140 nM (IC <sub>50</sub> )	AURKB/INCENP 98 nM (IC <sub>50</sub> )	TIE2/TEK 22 nM (IC <sub>50</sub> )
	TRKA 6 nM (IC <sub>50</sub> )	TRKB 9 nM (IC <sub>50</sub> )		

<b>In Vitro</b>	CFI-400945 (compound 48) shows potent inhibitory activities against a panel of kinases, including PLK4, TRKA, TRKB, AURKA, AURKB/INCENP, and TIE2/TEK, with IC <sub>50</sub> s of 2.8, 6, 9, 140, 98, 22 nM, and EC <sub>50</sub> s of 12, 84, 88, 510, 102, 117 nM, respectively. CFI-400945 exhibits growth inhibition effects on breast, lung, ovarian and colon cancer cells. The IC <sub>50</sub> s (in μM) are as follows: SKBr-3 (5.3), Cal-51 (0.26), BT-20 (0.058), A549 (0.005), OVCAR-3 (0.018), SW620 (0.38), Colo-205 (0.017), and HCT116+/- (0.004) [1]. CFI-400945 inhibits autophosphorylation of PLK4 at serine 305 with an EC <sub>50</sub> value of 12.3 nM in cells overexpressing PLK4. Cancer cells treated with CFI-400945 exhibit effects consistent with PLK4 kinase inhibition, including dysregulated centriole duplication, mitotic defects, and cell death[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Oral administration of CFI-400945 (3.0, 9.4 mg/kg) to mice bearing human cancer xenografts results in the significant inhibition of tumor growth at doses that are well tolerated. Increased antitumor activity is observed in PTEN-deficient compared to PTEN wild-type cancer xenografts. The maximum tolerated dose for once-daily administration of CFI-400945 is estimated to be 7.5-9.5 mg/kg[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

<b>Kinase Assay</b> [1]	Active PLK4 is purified and used to measure PLK4 activity, using an indirect ELISA detection system. PLK1, PLK2, PLK3, AURKA, and AURKB/INCENP compound inhibition are determined using FRET-based homogeneous assay kits from Invitrogen. The assays are performed with ATP concentrations of 25, 60, and 80 μM, respectively, for PLK1, PLK2, and PLK3 and ATP concentrations of 20 and 128 μM, respectively, for AURKA and AURKB/INCENP[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. <b>Caution: Product has not been fully validated for medical applications. For research use only.</b>
<b>Cell Assay</b> [2]	MDA-MB-468, MCF7, HCC1954, MDA-MB-231, SKBr-3, Cal-51, and BT-20 breast cancer cells are treated with 10 nM to 50 μM CFI-400945 for 5 days. Cell viability is measured using SRB assay[2]. Address: Deep Eddy, Suite 2, Monmouth Junction, NJ 08852, USA MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>Animal Administration</b> [2]	To treat an established tumor, CFI-400945 and the vehicle (water) are administered by oral gavage (2.5-20 mg/kg), and 5-FU and carboplatin are administered by intraperitoneal injection to mice as described in the text. Animal weights are monitored daily, and tumor volume is measured three times per week[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Nat Nanotechnol. 2021 Jul;16(7):830-839.
- Int J Mol Med. 2021 Jan;47(1):151-160.
- J Cancer Res Clin Oncol. 2020 Nov;146(11):2871-2883.
- Ir J Med Sci. 2022 May 4.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Sampson PB, et al. The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S)-2-(3-((E)-4-(((cis)-2,6-dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5<sup>1</sup>-methoxyspiro[cyclopropane-1,3<sup>1</sup>-indolin]-2<sup>7</sup>-one (CFI-400945) as a potent, orally active antitumor agent. J Med Chem. 2015 Jan 8;58(1):147-69.
- [2]. Mason JM, et al. Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent. Cancer Cell. 2014 Aug 11;26(2):163-76.